47.78
0.63 (1.34%)
新闻情绪
-
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
12 Nov, 8:14PM
-
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
07 Nov, 3:15PM
-
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
04 Nov, 6:30AM
-
Arrowhead Research: Fiscal Q4 Earnings Snapshot
12 Nov, 3:22PM
-
Arrowhead Pharmaceuticals falls on earnings miss
12 Nov, 4:03PM
AIStockmoo 评分
| 价值 30% | -1.4 |
| 盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -3.1 |
| 过去一年呈上升趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。近期突破阻力位尚未获得确认。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | -0.1 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 1.4 |
| 机构在最新13F申报中净+1.69%的股份:257家增持,268家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+22.9%,回补天数8.5天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利有升有降。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期动能下降。 参考 | |
| 支撑与阻力没有明确信号。 参考 | |
| 最终评分 | -1.29 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Arrowhead Pharmaceuticals, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| ARWR | - | - | - | 134.18 | -1.3 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| FOLD | 5 B | - | - | - | 0.0 |
| ARQT | 3 B | - | 119.82 | 14.26 | -0.1 |
|
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 13.02% |
| 机构持股比例 | 77.19% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 96.54%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 257 | 14,798,342 |
| 减持 | 268 | 13,553,768 |
| 新建仓 | 83 | 4,488,008 |
| 清仓 | 84 | 3,346,457 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 11,583,518 | 8.5 |
| 15 Oct 2026 | 10,959,276 | 5.4 |
| 30 Sep 2026 | 10,760,463 | 4.0 |
| 15 Sep 2026 | 9,272,290 | 5.1 |
| 31 Aug 2026 | 9,426,449 | 8.8 |
| 14 Aug 2026 | 9,207,426 | 7.8 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Arrowhead (ARWR) Q4 2026 Earnings Call Transcript
Plozasiran launch prep and a multibillion sHTG opportunity come into focus. |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments. On its fiscal 2026 earnings call, manag… |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals falls on earnings miss
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported fiscal year 2026 results that fell short of Wall Street expectations, with the stock declining 2.4% in after-hours trading Thursday. |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Research: Fiscal Q4 Earnings Snapshot
(AP) — Arrowhead Research Corp. (ARWR) on Thursday reported a loss of $428 million in its fiscal fourth quarter. |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
PASADENA, Calif., November 12, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results. |
| 09 Nov 2026 | Yahoo Finance |
Is Arrowhead Pharmaceuticals (ARWR) Worth Its Price After UK Approval?
Arrowhead Pharmaceuticals has had a bumpy share price journey lately, which puts a fresh spotlight on one simple question for investors who follow drug developers that rely heavily on future product uptake: is today’s valuation supported by its sales base? Over the past 3 years the stock has… |
| 09 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif., November 09, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:… |
| 07 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
PASADENA, Calif., November 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included… |
| 04 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
PASADENA, Calif., November 04, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and… |
| 03 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
PASADENA, Calif., November 03, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026… |
| 02 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif., November 02, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago. |
| 31 Oct 2026 | Yahoo Finance |
3 Biotech Stocks With Upside Of Up To 80%
Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech stocks with solid finances come into focus. This article… |
| 28 Oct 2026 | Yahoo Finance |
Arrowhead gains UK marketing authorisation for Redemplo
The regulatory approval covers patients diagnosed through either genetic testing or clinical criteria. |
| 27 Oct 2026 | Yahoo Finance |
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif., October 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS… |
| 23 Oct 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for… |
| 16 Oct 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
Arrowhead Pharmaceuticals (ARWR) drew fresh attention after announcing interim Phase 1/2a data for ARO-MAPT, which showed deep and durable cerebrospinal fluid tau reductions in healthy volunteers using subcutaneous RNA interference delivery across the blood brain barrier. Arrowhead Pharmaceuticals… |
| 15 Oct 2026 | Yahoo Finance |
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Interim Data for ARO-MAPT Shows Promise for TRiM™ Platform in CNS Diseases On October 14, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced interim results for the Phase 1/2a study of ARO-MAPT, which is… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合